Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Float Short %

11.52

Margin Of Safety %

-26

Put/Call OI Ratio

1.56

EPS Next Q Diff

-1.14

EPS Last/This Y

2.88

EPS This/Next Y

2.3

Price

234.05

Target Price

222.45

Analyst Recom

1.17

Performance Q

65.75

Relative Volume

1.36

Beta

0.47

Ticker: KRYS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10KRYS199.591.711.0012206
2025-11-11KRYS2031.710.0512207
2025-11-12KRYS203.151.741.1812128
2025-11-13KRYS201.431.740.0612131
2025-11-14KRYS206.161.740.3412137
2025-11-17KRYS208.271.730.1012176
2025-11-18KRYS204.641.720.0512221
2025-11-19KRYS204.391.720.0612214
2025-11-20KRYS204.31.720.8012218
2025-11-21KRYS212.361.710.2112229
2025-11-24KRYS214.911.790.058367
2025-11-25KRYS216.71.620.038687
2025-11-26KRYS218.991.610.338704
2025-12-01KRYS215.351.610.448714
2025-12-02KRYS215.521.590.009092
2025-12-03KRYS217.911.590.079095
2025-12-04KRYS222.051.560.719159
2025-12-05KRYS234.071.560.179172
2025-12-08KRYS234.131.560.229168
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10KRYS199.530.7220.45.12
2025-11-11KRYS203.0013.1224.25.86
2025-11-12KRYS203.2013.1217.45.86
2025-11-13KRYS201.4313.1213.75.86
2025-11-14KRYS205.8813.1226.75.86
2025-11-17KRYS208.3713.1221.45.86
2025-11-18KRYS204.6513.1209.55.86
2025-11-19KRYS204.1013.1215.75.86
2025-11-20KRYS204.105.0217.86.00
2025-11-21KRYS212.095.0226.66.00
2025-11-24KRYS214.915.0216.16.00
2025-11-25KRYS216.975.0214.96.00
2025-11-26KRYS218.995.0214.36.00
2025-12-01KRYS215.195.0205.16.00
2025-12-02KRYS215.065.0210.36.00
2025-12-03KRYS217.465.0215.16.00
2025-12-04KRYS222.015.0219.16.00
2025-12-05KRYS234.135.0233.26.00
2025-12-08KRYS234.055.0- 6.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10KRYS-2.39-0.5811.60
2025-11-11KRYS-2.39-0.5811.60
2025-11-12KRYS-2.39-0.5811.57
2025-11-13KRYS-2.39-0.5811.57
2025-11-14KRYS-2.39-0.5811.56
2025-11-17KRYS-2.400.8411.56
2025-11-18KRYS-2.400.8411.56
2025-11-19KRYS-2.400.8411.56
2025-11-20KRYS-2.400.8411.56
2025-11-21KRYS-2.400.8411.59
2025-11-24KRYS-2.362.0111.59
2025-11-25KRYS-2.362.0111.59
2025-11-26KRYS-2.362.0111.52
2025-12-01KRYS-2.361.9911.52
2025-12-02KRYS-2.361.9911.52
2025-12-03KRYS-2.361.9911.52
2025-12-04KRYS-2.361.9911.52
2025-12-05KRYS-2.361.9911.52
2025-12-08KRYS-4.621.9611.52
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

2.66

Avg. EPS Est. Current Quarter

1.61

Avg. EPS Est. Next Quarter

1.52

Insider Transactions

-4.62

Institutional Transactions

1.96

Beta

0.47

Average Sales Estimate Current Quarter

105

Average Sales Estimate Next Quarter

120

Fair Value

174.36

Quality Score

91

Growth Score

38

Sentiment Score

98

Actual DrawDown %

0.3

Max Drawdown 5-Year %

-53.4

Target Price

222.45

P/E

35.11

Forward P/E

30.66

PEG

0.7

P/S

18.19

P/B

5.96

P/Free Cash Flow

40.99

EPS

6.67

Average EPS Est. Cur. Y​

6

EPS Next Y. (Est.)

8.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

53.3

Relative Volume

1.36

Return on Equity vs Sector %

-9.4

Return on Equity vs Industry %

5.5

EPS 1 7Days Diff

0.9

EPS 1 30Days Diff

1.08

EBIT Estimation

Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading